Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is a heterogeneous group of cancers characterized by their lack estrogen receptors, progesterone and the HER2 receptor. They are more aggressive than other subtypes, with higher mean tumor size, grade, worst five-year overall survival, highest rates recurrence metastasis. Developing targeted therapies for TNBC has been major challenge due to its heterogeneity, treatment still largely relies on surgery, radiation therapy, chemotherapy. In this review article, we efforts in developing TNBC, discuss insights gained from these efforts, highlight potential opportunities going forward. Accumulating evidence supports TNBCs as multi-driver cancers, which multiple oncogenic drivers promote cell proliferation survival. such would require drug combinations that simultaneously block drivers. A strategy designed generate mechanism-based combination discussed.